Literature DB >> 18197001

Endometrial glandular dysplasia and endometrial intraepithelial neoplasia.

Xiaofang Yi1, Wenxin Zheng.   

Abstract

PURPOSE OF REVIEW: In recent decades, progress has been made in defining endometrial precancers. Endometrial intraepithelial neoplasia has been widely accepted as a precancer of type I endometrial cancer, while endometrial glandular dysplasia is a newly described entity as a probable precancer of type II cancer. As endometrial intraepithelial neoplasia has been discussed more extensively in the literature, we focus more on the recent development of endometrial glandular dysplasia in this review. RECENT
FINDINGS: Serous endometrial intraepithelial carcinoma was previously considered as a putative precancer for endometrial serous carcinoma or uterine papillary serous carcinoma. It is now considered as an early form of endometrial serous carcinoma, however. Endometrial glandular dysplasia was found to be a better candidate for precancer for both endometrial serous and clear cell carcinomas, which meets almost all recently defined criteria for precancer. Biomarkers of p53 and IMP3 are helpful for the early detection of endometrial glandular dysplasia as well as type II endometrial cancers.
SUMMARY: Two types of endometrial cancers are derived from two different precancers. Type I endometrioid carcinoma develops from endometrial intraepithelial neoplasia, while type II derives most probably from endometrial glandular dysplasia. Recognition and correct detection of endometrial glandular dysplasia may deepen our understanding and improve prevention and clinical management for type II endometrial cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18197001     DOI: 10.1097/GCO.0b013e3282f2fd50

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  14 in total

1.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

2.  Factors associated with Type I and Type II endometrial cancer.

Authors:  Ashley S Felix; Joel L Weissfeld; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Faina Linkov
Journal:  Cancer Causes Control       Date:  2010-07-14       Impact factor: 2.506

3.  Nrf2 expression in endometrial serous carcinomas and its precancers.

Authors:  Ning Chen; Xiaofang Yi; Nisreen Abushahin; Shujie Pang; Donna Zhang; Beihua Kong; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2010-12-24

Review 4.  Histopathologic diagnosis of endometrial precancers: Updates and future directions.

Authors:  Hao Chen; Amanda L Strickland; Diego H Castrillon
Journal:  Semin Diagn Pathol       Date:  2021-12-10       Impact factor: 3.893

5.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

6.  [p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumor aggressiveness in humans].

Authors:  P J Wild
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

7.  Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium.

Authors:  Xi Zhang; Sharon X Liang; Lin Jia; Ning Chen; Oluwole Fadare; Peter E Schwartz; Beihua Kong; Wenxin Zheng
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

8.  p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.

Authors:  Peter J Wild; Kristian Ikenberg; Thomas J Fuchs; Markus Rechsteiner; Strahil Georgiev; Niklaus Fankhauser; Aurelia Noske; Matthias Roessle; Rosmarie Caduff; Athanassios Dellas; Daniel Fink; Holger Moch; Wilhelm Krek; Ian J Frew
Journal:  EMBO Mol Med       Date:  2012-06-08       Impact factor: 12.137

9.  Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Diagn Pathol       Date:  2008-02-08       Impact factor: 2.644

10.  Correlation of NQO1 and Nrf2 in Female Genital Tract Cancer and Their Precancerous Lesions (Cervix, Endometrium and Ovary).

Authors:  Nisreen Abdel Tawab Abdel Gaber Osman; Nehad M R Abd El-Maqsoud; Saad Abdelnaby A El Gelany
Journal:  World J Oncol       Date:  2015-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.